GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » GenMark Diagnostics Inc (NAS:GNMK) » Definitions » Financial Strength

GenMark Diagnostics (GenMark Diagnostics) Financial Strength : 0 (As of Dec. 2020)


View and export this data going back to 2010. Start your Free Trial

What is GenMark Diagnostics Financial Strength?

GenMark Diagnostics has the Financial Strength Rank of 0.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

GenMark Diagnostics did not have earnings to cover the interest expense. GenMark Diagnostics's debt to revenue ratio for the quarter that ended in Dec. 2020 was 0.43. As of today, GenMark Diagnostics's Altman Z-Score is 6.17.


Competitive Comparison of GenMark Diagnostics's Financial Strength

For the Medical Devices subindustry, GenMark Diagnostics's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GenMark Diagnostics's Financial Strength Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, GenMark Diagnostics's Financial Strength distribution charts can be found below:

* The bar in red indicates where GenMark Diagnostics's Financial Strength falls into.



GenMark Diagnostics Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

GenMark Diagnostics's Interest Expense for the months ended in Dec. 2020 was $-1.7 Mil. Its Operating Income for the months ended in Dec. 2020 was $-2.1 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2020 was $84.0 Mil.

GenMark Diagnostics's Interest Coverage for the quarter that ended in Dec. 2020 is

GenMark Diagnostics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

GenMark Diagnostics's Debt to Revenue Ratio for the quarter that ended in Dec. 2020 is

Debt to Revenue Ratio=Total Debt (Q: Dec. 2020 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(3.093 + 84.046) / 200.32
=0.43

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

GenMark Diagnostics has a Z-score of 6.17, indicating it is in Safe Zones. This implies the Z-Score is strong.

Good Sign:

Altman Z-score of 6.17 is strong.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GenMark Diagnostics  (NAS:GNMK) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

GenMark Diagnostics has the Financial Strength Rank of 0.


GenMark Diagnostics Financial Strength Related Terms

Thank you for viewing the detailed overview of GenMark Diagnostics's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


GenMark Diagnostics (GenMark Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
5964 La Place Court, Carlsbad, CA, USA, 92008-8829
GenMark Diagnostics Inc is a provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and optimize patient treatment. The company currently operates in one reportable business segment, which encompasses the development, manufacturing, sales, and support of instruments and molecular tests based on its proprietary eSensor detection technology. Its operations and assets are in the United States of America.
Executives
Tyler Jensen officer: SVP, Engineering and Tech Dev 5964 LA PLACE COURT CARLSBAD CA 92008
Christine Shaw officer: VP, Assay Development 5964 LA PLACE COURT CARLSBAD CA 92008
Alan Baer Maderazo officer: VP, Qual, Reg, & Clin Affairs 5964 LA PLACE COURT CARLSBAD CA 92008
Michael Gleeson officer: SVP, Corp. Accounts 5964 LA PLACE COURT, SUITE 100 CARLSBAD CA 92008
Sarah Hollis Winkler officer: VP, Human Resources 5964 LA PLACE COURT CARLSBAD CA 92008
Michael John Harkins officer: SVP, Sales 5964 LA PLACE COURT CARLSBAD CA 92008
John Frederick Ek officer: Chief Financial Officer 5964 LA PLACE COURT, CARLSBAD CA 92008
Scott Mendel director, officer: President & CEO 5964 LA PLACE COURT, ADDRESS 2, CARLSBAD CA 92008
Eric Stier officer: SVP & General Counsel 5964 LA PLACE COURT CARLSBAD CA 92008
Brian Andrew Mitchell officer: SVP, Operations 5964 LA PLACE COURT CARLSBAD CA 92008
Daryl Faulkner director 5964 LA PLACE COURT, CARLSBAD CA 92008
Michael Kagnoff director DLA PIPER LLP (US) 4365 EXECUTIVE DRIVE, SUITE 1100 SAN DIEGO CA 92121
Lisa M. Giles director DURATA THERAPEUTICS, INC., 200 SOUTH WACKER DRIVE SUITE 2550, CHICAGO IL 60606
Kevin C Oboyle director 5964 LA PLACE COURT, CARLSBAD CA 92008
James Fox director 5964 LA PLACE COURT, CARLSBAD CA 92008